TRexBio announced a $50 million extension to its Series B to fund testing of TRB‑061 and other Treg‑centric programs. TRB‑061, currently in Phase 1, targets TNFR2 to activate regulatory T cells (Tregs) as a precision approach to control inflammation in atopic dermatitis and other immune disorders. Investors included Janus Henderson, Alexandria Venture Investments and Eli Lilly. TRexBio’s raise accelerates a wave of companies pursuing targeted immune‑modulation strategies that aim to reduce broad immunosuppression and address unmet needs in chronic inflammatory diseases. The financing will also support two additional preclinical programs moving toward first‑in‑human studies next year.